{
    "clinical_study": {
        "@rank": "158120", 
        "acronym": "MAP", 
        "arm_group": [
            {
                "arm_group_label": "Quetiapine", 
                "arm_group_type": "Experimental", 
                "description": "Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed."
            }, 
            {
                "arm_group_label": "Haloperidol", 
                "arm_group_type": "Active Comparator", 
                "description": "Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed."
            }
        ], 
        "brief_summary": {
            "textblock": "The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an\n      atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic\n      disorder, in individuals with MAP."
        }, 
        "brief_title": "Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Methamphetamine-induced Psychosis", 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Shared Paranoid Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e.\n      treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at\n      least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per\n      day orally once a day for four weeks. The doses will be increased every 5 days until no\n      psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common\n      antipsychotic adverse events will be checked and documented daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Having a psychotic episode with current use of methamphetamine\n\n          -  Positive urine toxicology test for methamphetamine on the first day of\n             hospitalization\n\n        Exclusion Criteria:\n\n          -  Using other illegal substances\n\n          -  Having a history of primary psychotic disorders or using antipsychotic agents\n\n          -  Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy,\n             stroke"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939093", 
            "org_study_id": "NRCT-53069"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Quetiapine", 
                    "Haloperidol"
                ], 
                "description": "If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.", 
                "intervention_name": "Diazepam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Quetiapine", 
                    "Haloperidol"
                ], 
                "description": "All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.", 
                "intervention_name": "Vitamin B1-6-12", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Quetiapine", 
                    "Haloperidol"
                ], 
                "description": "All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.", 
                "intervention_name": "Stugeron", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cinnarizine", 
                "Diazepam", 
                "Haloperidol", 
                "Methamphetamine", 
                "Haloperidol decanoate", 
                "Quetiapine", 
                "Thiamine", 
                "Vitamin B Complex", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Quetiapine", 
            "Haloperidol", 
            "Methamphetamine", 
            "Psychosis"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pathumthani", 
                    "country": "Thailand"
                }, 
                "name": "Thanyarak Institute on Drug Abuse"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis", 
        "overall_official": {
            "affiliation": "Thanyarak Institute on Drug Abuse", 
            "last_name": "Viroj Verachai, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: National Research Council of Thailand", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Positive and Negative Syndrome Scale", 
                "safety_issue": "No", 
                "time_frame": "Every day in Week 1."
            }, 
            {
                "measure": "Positive and Negative Syndrome Scale", 
                "safety_issue": "No", 
                "time_frame": "Every two days in Week 2 and 3."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939093"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Rasmon Kalayasiri", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Antipsychotic Adverse Event Form", 
            "safety_issue": "Yes", 
            "time_frame": "Every day for three weeks."
        }, 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Thanyarak Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Research Council of Thailand", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}